Danish authorities have already paid out DKK 800,000 to four patients for serious side effects from Wegovy and Ozempic, with 43 total compensation claims pending, as a new suspected brain injury case now heads to European regulators for review.
The young woman whose suspected Wegovy-related brain injury made headlines this week is not the first Danish patient to win compensation for neurological damage from the weight-loss drug. Patienterstatningen has already granted payment to another woman for permanent cognitive impairment and sensory disturbances after a Wegovy course, setting her permanent injury degree at 12 percent. That case is one of five decided so far from a pile of 43 claims alleging serious harm from semaglutide drugs.
Four of those five claims have been approved, paying out a combined DKK 800,000 for the rare eye disease NAION, which can cause permanent vision loss. The legal standard is high: it must be more likely than not that the drug caused the injury. Danish law entitles patients to compensation even if they were warned of the risk beforehand.
Denmark’s Conservative Turn
Denmark was only the second country in the world to approve Wegovy in December 2022. Now, less than four years later, the Danish Health Authority insists weight-loss medicines should play only a minor role in obesity treatment. The official June 2025 assessment acknowledges that Wegovy produces 9.6 to 15.8 percent average weight loss over two years when combined with a 500 calorie daily deficit. But it also notes that weight plateaus after about a year and most patients regain it after stopping.
The cardiovascular benefit is modest by Danish standards. According to Sundhedsstyrelsen, 65 patients with heart disease and overweight must be treated with Wegovy for four years to prevent one cardiovascular event or death. That number-needed-to-treat is above the threshold the authority uses to judge diabetes drugs clinically relevant.
Danish prescriptions for slimming medicine plunged from 72,000 in December 2023 to 60,000 in January 2024, a 17 percent drop in a single month. The timing coincides with public debates over supply shortages and reimbursement policy. No general subsidy exists for Wegovy in Denmark, leaving most users to pay out of pocket.
Brain Injury Now Under EU Review
The Danish Medicines Agency has escalated the latest brain injury case to the European Medicines Agency. Anton Pottegård, a leading Danish pharmacovigilance professor, told Dagens Medicin that the suspected chain from Wegovy-induced vomiting to brain damage is medically plausible. But he stressed that a single case cannot prove causality and must be rigorously assessed at EU level.
NAION is estimated to affect fewer than one in 10,000 semaglutide users. Other recognised side effects include pancreatitis, gallstones and slower gastric emptying, which can increase surgical risk if patients are not properly fasted. Most users experience gastrointestinal problems, headaches and fatigue, frequent enough in trials to cause some to quit or fail to reach full dose.
What Internationals Should Know
Wegovy is approved only for adults with BMI above 30, or above 27 with weight-related conditions such as prediabetes or hypertension. Pharmacological therapy must not be first-line treatment. Danish guidance insists on diet and exercise first, reserving the drug for selected patients where lifestyle change has not worked.
Internationals without a registered GP face barriers to legitimate access. Off-label use of Ozempic for weight loss occurs, but official warnings and supply concerns make that a grey area. Some GPs accept it if patients are informed and diabetes supply is not disrupted, but the official line is clear: Ozempic is for diabetes.
Anyone who suspects a serious side effect can claim compensation through Patienterstatningen, regardless of nationality. The process requires medical documentation and can take months. Patients and doctors should also report adverse reactions to Lægemiddelstyrelsen, feeding Denmark’s data into EU-wide monitoring that shapes label changes across all member states.
Denmark’s cautious stance reflects both emerging safety signals and a health system philosophy that resists drug-first solutions. For expats used to more liberal prescribing elsewhere, the combination of strict eligibility rules, full cost and high-profile injury cases is a sharp reminder that Wegovy is not a lifestyle choice here. It is a last-resort medicine with serious, if rare, risks that Danish authorities are now documenting in detail.
